Nisa Investment Advisors LLC raised its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 92,237 shares of the pharmaceutical company’s stock after purchasing an additional 1,654 shares during the period. Nisa Investment Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $15,677,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in VRTX. Xact Kapitalforvaltning AB grew its stake in shares of Vertex Pharmaceuticals by 15.4% during the fourth quarter. Xact Kapitalforvaltning AB now owns 44,195 shares of the pharmaceutical company’s stock valued at $6,623,000 after buying an additional 5,882 shares during the last quarter. Dorsey Wright & Associates grew its stake in shares of Vertex Pharmaceuticals by 9.1% during the second quarter. Dorsey Wright & Associates now owns 16,510 shares of the pharmaceutical company’s stock valued at $2,806,000 after buying an additional 1,382 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Vertex Pharmaceuticals by 4.3% during the fourth quarter. Envestnet Asset Management Inc. now owns 33,620 shares of the pharmaceutical company’s stock valued at $5,038,000 after buying an additional 1,373 shares during the last quarter. GSA Capital Partners LLP grew its stake in shares of Vertex Pharmaceuticals by 27.6% during the first quarter. GSA Capital Partners LLP now owns 33,571 shares of the pharmaceutical company’s stock valued at $5,471,000 after buying an additional 7,264 shares during the last quarter. Finally, LPL Financial LLC grew its stake in shares of Vertex Pharmaceuticals by 15.9% during the fourth quarter. LPL Financial LLC now owns 43,026 shares of the pharmaceutical company’s stock valued at $6,448,000 after buying an additional 5,887 shares during the last quarter. Institutional investors and hedge funds own 93.38% of the company’s stock.

Vertex Pharmaceuticals opened at $177.40 on Friday, according to Marketbeat.com. The company has a current ratio of 3.68, a quick ratio of 3.53 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $45.90 billion, a P/E ratio of 150.10, a price-to-earnings-growth ratio of 2.35 and a beta of 1.42. Vertex Pharmaceuticals Incorporated has a 1 year low of $136.50 and a 1 year high of $183.39.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, April 26th. The pharmaceutical company reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.13. The company had revenue of $641.00 million for the quarter, compared to analysts’ expectations of $626.05 million. Vertex Pharmaceuticals had a return on equity of 15.28% and a net margin of 9.36%. Vertex Pharmaceuticals’s quarterly revenue was down 10.2% on a year-over-year basis. During the same period last year, the firm earned $0.99 earnings per share. analysts anticipate that Vertex Pharmaceuticals Incorporated will post 1.94 EPS for the current fiscal year.

A number of brokerages have recently issued reports on VRTX. Jefferies Financial Group raised their price objective on Vertex Pharmaceuticals to $210.00 and gave the company a “buy” rating in a research note on Monday, July 16th. Zacks Investment Research raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $178.00 price objective on the stock in a research note on Saturday, June 30th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Sunday, July 1st. BidaskClub cut Vertex Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, March 30th. Finally, Maxim Group reaffirmed a “buy” rating and set a $200.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, April 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and twenty-three have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $189.42.

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 4,096 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, June 29th. The stock was sold at an average price of $167.63, for a total transaction of $686,612.48. Following the sale, the executive vice president now directly owns 48,603 shares of the company’s stock, valued at approximately $8,147,320.89. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Paul M. Silva sold 860 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $179.85, for a total value of $154,671.00. Following the sale, the senior vice president now directly owns 16,947 shares in the company, valued at $3,047,917.95. The disclosure for this sale can be found here. Insiders sold 325,198 shares of company stock worth $52,264,134 over the last three months. 1.80% of the stock is owned by insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

Recommended Story: Book Value Of Equity Per Share – BVPS Explained

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.